Publication date: November 2018
Source: Molecular Immunology, Volume 103
Author(s): D.A. Diaz-Dinamarca, D.A. Soto, Y.Y. Leyton, M.J. Altamirano-Lagos, M.J. Avendaño, A.M. Kalergis, A.E. Vasquez
Abstract
The Surface Immunogenic Protein (SIP) of Group B Streptococcus (GBS) had been described as a good target for vaccine development. To date, SIP has been reported as a highly conserved protein, and in a mouse model it induces protection against lethal GBS challenge. Also, similar effects have been described by intranasal immunization with a SIP-based vaccine. In this study, we show the immune response induced by an oral SIP-based vaccine formulated on alum in a mouse model. Our vaccine can reduce vaginal GBS colonization and induce specific SIP-antibodies with opsonophagocytosis activities against GBS. Moreover, we observed the activation of T-cells producing IFN-γ, TNF-α, IL-10, IL-2, and increased expression of the transcription factor T-bet, suggesting a Th1-type humoral response. The oral SIP-based vaccine is a novel alternative in the development of a vaccine against GBS.
https://ift.tt/2wYbjiL
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου